Extended Data Fig. 8: Functional effects of in vitro antibody-peptide inhibitor conjugate treatment of tumor cells.
From: Antibody–peptide conjugates deliver covalent inhibitors blocking oncogenic cathepsins
a, b) CD74 accumulation measured by flow cytometry in Karpas-422 (a, n = 4 independent wells per condition) and Raji (b, n = 6 independent wells per condition) cells after 48 h incubation with APIC (red), unconjugated antibody (grey) or PBS (black). Median fluorescence intensity (MFI) normalized to PBS condition. P-value was determined by two-tailed t-test. c) CD74 accumulation measured by flow cytometry in Karpas-422 and WSU-DLCL2 cells overexpressing CTSS Y132D mutant form, after a 48 h treatment with αCD22 APIC. MFI normalized to signal in control antibody-treated cells (n = 2 independent wells treated per condition). d) Quantification of FRET assay assessing murine CTSS inhibition at increasing NNPI-C10 concentrations (n = 3 independent replicates; mean and SD values are shown). e) Murine CTSS inhibition in A20 cells treated with αCD79 APIC or petesicatib, assessed by BMV109 qABP. Lysate from untreated CTSS KO A20 cells was loaded as control.
